JP2001501823A - 疾病関連プロテインチロシンホスファターゼ - Google Patents

疾病関連プロテインチロシンホスファターゼ

Info

Publication number
JP2001501823A
JP2001501823A JP10516912A JP51691298A JP2001501823A JP 2001501823 A JP2001501823 A JP 2001501823A JP 10516912 A JP10516912 A JP 10516912A JP 51691298 A JP51691298 A JP 51691298A JP 2001501823 A JP2001501823 A JP 2001501823A
Authority
JP
Japan
Prior art keywords
hptp
sequence
polypeptide
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10516912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001501823A5 (enExample
Inventor
ゴリ、スリヤ・ケイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Publication of JP2001501823A publication Critical patent/JP2001501823A/ja
Publication of JP2001501823A5 publication Critical patent/JP2001501823A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP10516912A 1996-10-03 1997-10-02 疾病関連プロテインチロシンホスファターゼ Ceased JP2001501823A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/725,532 US6020179A (en) 1996-10-03 1996-10-03 Nucleic acids encoding human tyrosine phosphatases
US08/725,532 1996-10-03
PCT/US1997/017890 WO1998014596A2 (en) 1996-10-03 1997-10-02 Disease associated protein tyrosine phosphatases

Publications (2)

Publication Number Publication Date
JP2001501823A true JP2001501823A (ja) 2001-02-13
JP2001501823A5 JP2001501823A5 (enExample) 2005-06-16

Family

ID=24914927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10516912A Ceased JP2001501823A (ja) 1996-10-03 1997-10-02 疾病関連プロテインチロシンホスファターゼ

Country Status (6)

Country Link
US (1) US6020179A (enExample)
EP (1) EP0951556A2 (enExample)
JP (1) JP2001501823A (enExample)
AU (1) AU4667397A (enExample)
CA (1) CA2265449A1 (enExample)
WO (1) WO1998014596A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156551A (en) * 1998-06-05 2000-12-05 Beth Israel Deaconess Medical Center Activated mutants of SH2-domain-containing protein tyrosine phosphatases and methods of use thereof
US6258582B1 (en) * 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
AU6410599A (en) * 1998-09-30 2000-04-17 Millennium Pharmaceuticals, Inc. Novel protein phosphatase molecules and uses therefor
DE10015818A1 (de) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6465632B1 (en) * 2000-06-09 2002-10-15 Lexicon Genetics Incorporated Human phosphatases and polynucleotides encoding the same
CN1331327A (zh) * 2000-06-26 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人纹状体富集磷酸酶14.85和编码这种多肽的多核苷酸
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
US7744867B2 (en) * 2001-05-31 2010-06-29 The Cleveland Clinic Foundation PTPase inhibitors and method of using same
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
WO2003070158A2 (en) * 2001-09-07 2003-08-28 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
US20030161893A1 (en) * 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
WO2003031930A2 (en) * 2001-10-09 2003-04-17 The Johns Hopkins University A phosphatase associated with metastasis
WO2003092616A2 (en) * 2002-05-01 2003-11-13 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US8435959B2 (en) 2004-03-29 2013-05-07 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2007082052A2 (en) * 2006-01-11 2007-07-19 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6688696A (en) * 1995-08-10 1997-03-05 Incyte Pharmaceuticals, Inc. Non-receptor type human protein tyrosine phosphatase

Also Published As

Publication number Publication date
WO1998014596A2 (en) 1998-04-09
CA2265449A1 (en) 1998-04-09
EP0951556A2 (en) 1999-10-27
AU4667397A (en) 1998-04-24
US6020179A (en) 2000-02-01
WO1998014596A3 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
JP2001501823A (ja) 疾病関連プロテインチロシンホスファターゼ
JP2000515734A (ja) ヒトｃＡＭＰ依存性プロテインキナーゼインヒビターホモログ
JP2002507124A (ja) ヒト細胞外基質タンパク質
JP2002527069A (ja) プロテインキナーゼホモログ
JP2001515349A (ja) Ｔｍ４ｓｆヒト腫瘍関連抗原
JP2000517173A (ja) 二つのヒトｎｓｐ様タンパク質
JP2001520512A (ja) ヒト・ホスホリパーゼインヒビター
JP2001514657A (ja) 成長因子受容体結合タンパク質
JP2000507817A (ja) ヒト細胞死関連タンパク質
JP2003527815A (ja) 細胞増殖関連分子
JP2001526914A (ja) ヒト・調節タンパク質
JP2002509427A (ja) 新規なヒト・レプチンレセプター遺伝子関連タンパク質
JP2001514495A (ja) ヒト・ナトリウム依存性リン酸塩同時輸送体
JP2000514645A (ja) ヒト・プロテインキナーゼｃインヒビターホモログ
JP2001525675A (ja) 腫瘍関連抗原
JP2001511645A (ja) ヒトＣ５ａ様受容体
JP2000515762A (ja) 新規なヒトｍＲＮＡ校正酵素
JP2001513640A (ja) 新規なヒト膜貫通４スーパーファミリータンパク質
JP2001502532A (ja) 新規なヒト・ホスホレンマン様タンパク質
JP2001509015A (ja) ヒト塩素イオンチャネルタンパク質（ｈｃｃｐ）
JP2000517170A (ja) 新規なヒトマクロファージ抗原
US5843715A (en) Human proteasome subunit proteins
JP2001520015A (ja) ヒト・マンモグロビンホモログ
JP2001517093A (ja) 成長因子様タンパク質をコードするポリヌクレオチド
JP2002512527A (ja) ヒト・プレプロタキキニンｂ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070327

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070925